Podium to Practice: ESMO® 2025 – Melanoma: Pathological Response to A Single Dose of Neoadjuvant Nivolumab
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
1604O – Randomization to Adjuvant Nivolumab or Ipilimumab + Nivolumab Based on Pathological Response to A Single Dose of Neoadjuvant Nivolumab in Stage III melanoma
Studies/trials discussed:
1604O – Randomization to Adjuvant Nivolumab or Ipilimumab + Nivolumab Based on Pathological Response to A Single Dose of Neoadjuvant Nivolumab in Stage III melanoma
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.